Phase 1 Non-alcoholic Fatty Liver Disease NAFLD Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
Evaluating the Pharmacokinetics and Safety of Miricorilant
Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 1
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Type 2 Diabetes Mellitus (T2DM)Non-alcoholic Fatty Liver Disease NAFLD
1Globe Health Institute52 enrolled1 locationNCT06694935